Tags

Type your tag names separated by a space and hit enter

[Pregabalin--profile of efficacy and tolerability in neuropathic pain].
Drugs Today (Barc). 2009 Oct; 45 Suppl C:19-27.DT

Abstract

Pregabalin (PGB), like its predecessor gabapentin, is a structural analogue (but not functional) of the gammaaminobutyric acid (GABA). PGB has analgesic, antoconvulsivant, and ansiolytic activities. Neuropathic pain (NP) initial recommended dose is 150 mg per day. Depending on the patient response or bodily resistance to the drug the initial dose can be increased up to 300 mg per day (divided in 2-3 daily doses) during a one-week period. PGB is quickly absorbed in the digestive system with high oral biodisponibility. The drug is eliminated almost exclusively by renal excretion (98%). PGB efficacy was evaluated by several studies by means of visual analog scales (VAS) in several NP conditions such as post-herpetic neuropathy (PHN) or painful diabetic neuropathy (PDN). When compared with placebo, PGB provided significant benefit with 150 mg doses in the treatment of PHN pain. In studies developed in patients with PDN, the significant difference between placebo and treatment group only was achieved in individuals with daily doses of 300 mg/day, and the response was clearly dose-dependent. Tolerability information obtained from a number of studies has shown that the drug has a very good safety and tolerability profile. Side effects were mild to moderate and dose-dependent. Based on controlled studies, the main adverse effects observed with PGB are dizziness (23.1%), drowsiness (14.6%), and peripheral aedema (10.4%). As these side effects are dosedependent, they can be easily managed by a simple dose reduction, with no need to discontinue the therapy. Thus, according to efficacy and tolerability data, PGB is an important therapeutic option in NP treatment.

Authors+Show Affiliations

Médico fisiatra do Instituto Lauro De Souza Lima de Bauru. Médico fisiatra do Grupo de Dor da Neurologia do HC da FMUSP.

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

por

PubMed ID

20087482

Citation

Stump, Patrick. "[Pregabalin--profile of Efficacy and Tolerability in Neuropathic Pain]." Drugs of Today (Barcelona, Spain : 1998), vol. 45 Suppl C, 2009, pp. 19-27.
Stump P. [Pregabalin--profile of efficacy and tolerability in neuropathic pain]. Drugs Today (Barc). 2009;45 Suppl C:19-27.
Stump, P. (2009). [Pregabalin--profile of efficacy and tolerability in neuropathic pain]. Drugs of Today (Barcelona, Spain : 1998), 45 Suppl C, 19-27.
Stump P. [Pregabalin--profile of Efficacy and Tolerability in Neuropathic Pain]. Drugs Today (Barc). 2009;45 Suppl C:19-27. PubMed PMID: 20087482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pregabalin--profile of efficacy and tolerability in neuropathic pain]. A1 - Stump,Patrick, PY - 2010/1/21/entrez PY - 2010/1/21/pubmed PY - 2010/2/19/medline SP - 19 EP - 27 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today (Barc) VL - 45 Suppl C N2 - Pregabalin (PGB), like its predecessor gabapentin, is a structural analogue (but not functional) of the gammaaminobutyric acid (GABA). PGB has analgesic, antoconvulsivant, and ansiolytic activities. Neuropathic pain (NP) initial recommended dose is 150 mg per day. Depending on the patient response or bodily resistance to the drug the initial dose can be increased up to 300 mg per day (divided in 2-3 daily doses) during a one-week period. PGB is quickly absorbed in the digestive system with high oral biodisponibility. The drug is eliminated almost exclusively by renal excretion (98%). PGB efficacy was evaluated by several studies by means of visual analog scales (VAS) in several NP conditions such as post-herpetic neuropathy (PHN) or painful diabetic neuropathy (PDN). When compared with placebo, PGB provided significant benefit with 150 mg doses in the treatment of PHN pain. In studies developed in patients with PDN, the significant difference between placebo and treatment group only was achieved in individuals with daily doses of 300 mg/day, and the response was clearly dose-dependent. Tolerability information obtained from a number of studies has shown that the drug has a very good safety and tolerability profile. Side effects were mild to moderate and dose-dependent. Based on controlled studies, the main adverse effects observed with PGB are dizziness (23.1%), drowsiness (14.6%), and peripheral aedema (10.4%). As these side effects are dosedependent, they can be easily managed by a simple dose reduction, with no need to discontinue the therapy. Thus, according to efficacy and tolerability data, PGB is an important therapeutic option in NP treatment. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/20087482/[Pregabalin__profile_of_efficacy_and_tolerability_in_neuropathic_pain]_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=4669 DB - PRIME DP - Unbound Medicine ER -